Background/aim: Since January 2020, coronavirus disease (COVID-19) cases have been confirmed in Japan, and the number of patients with COVID-19 has been increasing. Two emergency declarations have been made previously and one is currently in effect. Based on our experience of a situation that could affect cancer treatment, this study retrospectively examined the correlation between perioperative anticancer therapy and COVID-19 incidence in patients with breast cancer.
Patients And Methods: Patients who underwent perioperative anticancer therapy for breast cancer at our hospital from February 2020 to February 2021 were included in this study. The presence or absence of COVID-19, timing of anticancer drug initiation, and clinical data were collected.
Results: No cases of COVID-19 were diagnosed in patients receiving perioperative anticancer therapy at our hospital.
Conclusion: Regimen modification, active use of supportive care, and patient lifestyle were factors reducing the incidence of COVID-19.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.21873/anticanres.14994 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Exploring the Unique Role of Specialized Pro-Resolving Mediators in Cancer Therapeutics.
Prostaglandins Other Lipid Mediat
December 2024
Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215; Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215.
Unresolved chronic inflammation, a hallmark of cancer, promotes tumor growth and metastasis in various cancer types. In contrast to blocking inflammation, stimulation of resolution of inflammation is an entirely novel approach to "resolve" inflammation. Resolution of inflammation mechanisms in cancer includes clearance of tumor debris, counter-regulation of pro-inflammatory eicosanoids and cytokines, and suppression of leukocyte infiltration.
View Article and Find Full Text PDFIntratumoral Treatment in Lung Cancer: Is It Time to Move Towards Clinical Practice?
Cancers (Basel)
November 2024
Medical Oncology Unit, Fondazione IRCCS San Gerardo dei Tintori, 20900 Monza, Italy.
According to a modern view, cancer no longer follows a purely mechanistic model. Rather, a tumor is conceived as a more complex structure, composed of cancer cells, the activities of which may interact and reshape the so-called tumor microenvironment (TME), leading to preservation of specific tumoral niches and promoting the survival of tumoral stem cells. : Therapeutic strategies must deal with this unique cancer architecture in the near future by widening their range of activities outside the cancer cells and rewiring a TME to ensure it is hostile to cancer growth.
View Article and Find Full Text PDF[Chinese expert consensus on standardized treatment of presacral cyst(2024 edition)].
Zhonghua Zhong Liu Za Zhi
December 2024
Article Synopsis
- Surgical excision is the main treatment for presacral cysts, but it's challenging due to nearby blood vessels and nerves, which can lead to complications and recurrence if done incorrectly.
- The Chinese Expert Consensus on the Standardized Diagnosis and Treatment of Presacral Cysts (2024 edition) was developed by a team of specialists to address these challenges and improve patient outcomes.
- Key updates in the 2024 consensus include new classifications for cyst anatomy, a focus on protecting sacral nerves during surgery, and clearer surgical approaches for different types of cysts.
Cancer-Related Coagulopathy and Perioperative Considerations.
Anesth Analg
December 2024
From the Department of Anesthesiology, University of Maryland School of Medicine, Baltimore, Maryland.
Article Synopsis
- Cancer-related coagulation abnormalities lead to imbalances in the hemostatic system, increasing risks of both blood clots and bleeding, which raises patient morbidity and mortality.
- Improved cancer treatments have resulted in better survival rates and an aging population of cancer survivors, thus increasing the overall number of patients requiring surgical procedures.
- Anesthesiologists need to be knowledgeable about the types and effects of cancer-related coagulation issues to effectively manage the perioperative care of these high-risk patients.
Perioperative Anemia Is an Independent Prognostic Factor for Gastric Cancer Patients Who Receive Curative Treatment.
Anticancer Res
December 2024
Department of Surgery, Yokohama City University, Yokohama, Japan.
Background/aim: This study evaluated the clinical impact of anemia during the perioperative period on both short- and long-term oncological outcomes in resectable gastric cancer (GC) patients who received curative treatment.
Patients And Methods: We conducted a retrospective review of medical records and collected data from consecutive patients with gastric cancer who underwent curative resection at Yokohama City University between 2015 and 2022.
Results: A total of 330 patients were evaluated in this study.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!